Nitazoxanide: A new thiazolide antiparasitic agent

Clinical Infectious Diseases

Volumn 40, Issue 8, 2005, Pages 1173-1180

  Fox, Leanne M ^a,b,d   Saravolatz, Louis D ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; AZITHROMYCIN; GLUCURONIDE; MEBENDAZOLE; METRONIDAZOLE; NITAZOXANIDE; PRAZIQUANTEL; QUINFAMIDE; RIFAMPICIN; TIZOXANIDE; TIZOXANIDE GLUCURONIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANCYLOSTOMIASIS; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENTEROBIASIS; FASCIOLIASIS; FEVER; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GIARDIA LAMBLIA; GIARDIASIS; HELMINTHIASIS; HUMAN; IMMUNE DEFICIENCY; INCREASED APPETITE; INFECTION; MALAISE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTOZOAL INFECTION; PRURITUS; REVIEW; RHINITIS; SALIVARY GLAND DISEASE; SCLERA DISEASE; SIDE EFFECT; STRONGYLOIDIASIS; SWEATING; TREATMENT OUTCOME; TRICHURIASIS; URINE COLOR;

ANTIPARASITIC AGENTS; HUMANS; MOLECULAR STRUCTURE; PARASITIC DISEASES; THIAZOLES;

EID: 16844372587     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428839     Document Type: Review

References (45)

1. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 2002; 18:95-7.
2. Rossignol JF, Cavier R. New derivative of 2-benzamido-5-nitrothiazoles. Chem Abstr 1975; 83:28216n.
3. Abaza H, El-Zayadi A, Kabil SM, Rizk H. Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt. Curr Ther Res 1998; 59:116-21.
4. Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 1984; 33:511-2.
5. Rossignol JF, Maisonneuve H, Cho YW. Nitroimidazoles in the treatment of trichomoniasis, giardiasis and amoebiasis. Int J Clin Pharmacol Ther Toxicol 1984; 22:63-72
6. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru. Aliment Pharmacol Ther 2001; 15:1409-15.
7. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or Entamoeba dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:381-4.
8. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001; 184:103-6.
9. Rossignol JF, Abaza H, Friedman H. Successful treatment of human fascioliasis with nitazoxanide. Trans R Soc Trop Med Hyg 1998; 92:103-4.
10. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266-70.
11. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998; 42:2836-40.
12. Sisson G, Goodwin A, Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46:2116-23.
13. Theodos CM, Griffiths JK, D'Onfro J, Fairfield A, Tzipori S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob Agents Chemother 1998; 42:1959-65.
14. Gargala G, Delaunay A, Li X, Brasseur P, Favennec L, Ballet JJ. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells. J Antimicrob Chemother 2000; 46:57-60.
15. Giacometti A, Cirioni O, Barchiesi F, Ancarani F, Scalise G. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 2000; 45:453-6.
16. Cedillo-Rivera R, Chavez B, Gonzalez-Robles A, Tapia A, Yepez-Mulia L. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis, and Trichomonas vagtnalis trophozoites. J Eukaryot Microbiol 2002; 49:201-8.
17. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, and Trichomonas vaginalis. J Antimicrob Chemother 2002; 49:103-11.
18. Didier ES, Maddry JA, Kwong CD, Green LC, Snowden KF, Shadduck JA. Screening of compounds for antimicrosporidial activity in vitro. Folia Parasitol 1998; 45:129-39.
19. Vdovenka AA, Williams JE. Blastocystis hominis: neutral red supravital staining and its application to in vitro drug sensitivity testing. Parasitol Res 2000; 86:573-81.
20. Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47:467-74.
21. Walker M, Rossignol JF, Torgerson P, Hemphill A. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 2004; 53:1-8.
22. Abdel-Rahman MS, El-Bahy MM, El-Bahy NM. Testing the parasiticidal efficacy of nitazoxanide. Alex J Vet Sci 1997; 13:447-58.
23. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-8.
24. Yamamoto Y, Hakki A, Friedman H, et al. Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with antivacuolating toxin activity. Chemotherapy 1999; 45:303-12.
25. Stockis A, Allemon AM, DeBruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int J Clin Pharmacol Ther 2002; 40:213-20.
26. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000; 38:387-94.
27. Stockis A, Deroubaix X, Lins R, Jeanbaptiste B, Calderon P, Rossignol JF. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int J Clin Pharmacol Ther 1996; 34:349-51.
28. Prescribing information: Alinia. Tampa, FL: Romark Laboratories, 2004.
29. Stockis A, DeBruyn S, Gengler C, Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1g b.i.d. Int J Clin Pharmacol Ther 2002; 40:221-7.
30. Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet 2002; 360:1375-80.
31. Abdel-Maboud AI, Rossignol JF, el-Kady MS, Mostafa MS, Kabil SM. Cryptosporidiosis in Benha: study of some recent modalities in diagnosis and treatment. J Egypt Soc Parasitol 2000; 30:717-25.
32. Romero Cabello R, Guerroro LR, Munoz Garcia MR, Geyne Cruz A. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans R Soc Trop Med Hyg 1997; 91:701-3.
33. Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002; 66:251-1.
34. Rodriguez-Garcia R, Rodriguez-Guzman LM, Cruz del Castillo AH. Effectiveness and safety of mebendazole compared to nitazoxanide in the treatment of Giardia lamblia in children. Rev Gastroenterol Mex 1999; 64:122-6.
35. Abboud P, Lemee V, Gargala G, et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:1792-4.
36. Doumbo O, Rossignol JF, Pichard E, et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 1997; 56:637-9.
37. Rossignol JF, Hidalgo H, Feregrino M, et al. A double-blind placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998; 92:663-6.
38. Davis LJ, Soave R, Dudley RE, Fessel JW, Faulkner S, Mamakos JP. Nitazoxanide (NTZ) for AIDS-related cryptosporidial diarrhea (CD): an open-label safety, efficacy and pharmacokinetic study [abstract LM50]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996:289.
39. Tzipori S. Cryptosporidiosis: laboratory investigations and chemotherapy. Adv Parasitol 1998; 40:187-221.
40. Ortiz JJ, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002; 96:193-6.
41. Diaz E, Mondragon J, Ramirez E, Bernal R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68:384-5.
42. Kabil SM, Ashry EE, Ashraf NK. An open-label clinical study of nitazoxanide in the treatment of human fascioliasis. Curr Ther Res 2000; 61:339-45.
43. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of facioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003; 17:265-70.
44. Oscar Vasquez T, Ruben Alvarez C, Napoleon Gonzales S, et al. Diagnostico y tratamiento de infeccion por Cyclospora cayetanensis en patients pediatricos. Rev Gastroenterol Peru 1998; 18:116-120.
45. Bicart-See A, Massip P, Linas MD, Datry A. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob Agents Chemother 2000; 44:167-8.